Eikon Therapeutics EIK1001 Combination Shows 72.4% Response Rate
Eikon Therapeutics said its EIK1001 combination showed a 72.4% response rate in a squamous lung cancer trial.
Eikon Therapeutics said its EIK1001 combination showed a 72.4% response rate in a squamous lung cancer trial.